MCM4 as Potential Metastatic Biomarker in Lung Adenocarcinoma

<b>Background:</b> Lung adenocarcinoma (LUAD) is the most common subtype of non-small-cell lung cancer and is frequently diagnosed at advanced stages with metastasis, contributing to its poor prognosis. Identifying key metastasis-related biomarkers is critical for improving early diagnosis and therapeutic targeting. <b>Methods:</b> We analyzed four GEO microarray datasets (GSE32863, GSE27262, GSE40275, and GSE33356) and TCGA data to identify differentially expressed genes (DEGs) in LUAD. Functional enrichment of DEGs was analyzed using Gene Ontology, Kyoto Encyclopedia of Genes and Genomes analysis, and a Cancer Hallmark Enrichment Plot. Hub gene analysis was conducted using Cytoscape. Hub genes were evaluated for their expression, prognostic significance (via the Kaplan-Meier plotter), and clinical correlation using additional platforms (TCGA, Lung Cancer Explorer, TNMplot, and the Human Protein Atlas). <b>Results:</b> A total of 333 consistently dysregulated DEGs were identified, enriched in pathways related to metastasis, including angiogenesis, immune escape, and ECM interaction. Ten hub genes (<i>AURKA</i>, <i>TOP2A</i>, <i>CCNB2</i>, <i>CENPF</i>, <i>MCM4</i>, <i>TPX2</i>, <i>KIF20A</i>, <i>ASPM</i>, <i>MELK</i>, and <i>NEK2</i>) were identified through network analysis. Among these, <i>MCM4</i> showed strong upregulation in LUAD and was significantly associated with poor overall survival. Notably, <i>MCM4</i> expression also correlated with post-progression survival and markers of invasiveness. Immunohistochemistry and transcriptomic analyses confirmed <i>MCM4</i> overexpression at both mRNA and protein levels. Additionally, <i>MCM4</i> expression was positively correlated with various matrix metalloproteinases, supporting its role in promoting tumor invasiveness. <b>Conclusions:</b><i>MCM4</i> is a novel potential biomarker for LUAD metastasis and prognosis. Its consistent upregulation, association with metastatic markers, and clinical significance suggest it may serve as a candidate target for diagnostic use or therapeutic intervention in advanced LUAD.

Authors

Institutions

Publication Details

Journal
Diagnostics
Published
2025-06-18
DOI
https://doi.org/10.3390/diagnostics15121555
Citations
1
Primary Topic
RNA modifications and cancer
Type
article
Field-Weighted Citation Impact
0.81

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

MCM4 as Potential Metastatic Biomarker in Lung Adenocarcinoma

Thai‐Yen Ling, Tsung-Ming Chang, Ju‐Fang Liu, Hung-Chih Lai
1 citations
Diagnostics
RNA modifications and cancer
0.81
article

MCM4 as Potential Metastatic Biomarker in Lung Adenocarcinoma

Thai‐Yen Ling, Tsung-Ming Chang, Ju‐Fang Liu, Hung-Chih Lai
article en
1 citations

Abstract

<b>Background:</b> Lung adenocarcinoma (LUAD) is the most common subtype of non-small-cell lung cancer and is frequently diagnosed at advanced stages with metastasis, contributing to its poor prognosis. Identifying key metastasis-related biomarkers is critical for improving early diagnosis and therapeutic targeting. <b>Methods:</b> We analyzed four GEO microarray datasets (GSE32863, GSE27262, GSE40275, and GSE33356) and TCGA data to identify differentially expressed genes (DEGs) in LUAD. Functional enrichment of DEGs was analyzed using Gene Ontology, Kyoto Encyclopedia of Genes and Genomes analysis, and a Cancer Hallmark Enrichment Plot. Hub gene analysis was conducted using Cytoscape. Hub genes were evaluated for their expression, prognostic significance (via the Kaplan-Meier plotter), and clinical correlation using additional platforms (TCGA, Lung Cancer Explorer, TNMplot, and the Human Protein Atlas). <b>Results:</b> A total of 333 consistently dysregulated DEGs were identified, enriched in pathways related to metastasis, including angiogenesis, immune escape, and ECM interaction. Ten hub genes (<i>AURKA</i>, <i>TOP2A</i>, <i>CCNB2</i>, <i>CENPF</i>, <i>MCM4</i>, <i>TPX2</i>, <i>KIF20A</i>, <i>ASPM</i>, <i>MELK</i>, and <i>NEK2</i>) were identified through network analysis. Among these, <i>MCM4</i> showed strong upregulation in LUAD and was significantly associated with poor overall survival. Notably, <i>MCM4</i> expression also correlated with post-progression survival and markers of invasiveness. Immunohistochemistry and transcriptomic analyses confirmed <i>MCM4</i> overexpression at both mRNA and protein levels. Additionally, <i>MCM4</i> expression was positively correlated with various matrix metalloproteinases, supporting its role in promoting tumor invasiveness. <b>Conclusions:</b><i>MCM4</i> is a novel potential biomarker for LUAD metastasis and prognosis. Its consistent upregulation, association with metastatic markers, and clinical significance suggest it may serve as a candidate target for diagnostic use or therapeutic intervention in advanced LUAD.

DiagnosticsVol. 15(12)
National Taiwan University (TW), China Medical University (TW), China Medical University Hospital (TW), Taipei Medical University (TW)
Shin Kong Wu Ho-Su Memorial Hospital
Openalex Percentile: Top 27%
RNA modifications and cancer
0.81
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.